Beauty Farm Medical and Health Industry Inc. (BeautyFarm Med; HKEX: 02373) disclosed that it bought back 52,000 ordinary shares on 29 June 2026 via on-market transactions at prices between HK$16.40 and HK$16.78 per share. The volume-weighted average repurchase price was HK$16.6127, bringing the cash outlay to HK$0.86 million.

The repurchased shares, representing 0.0209% of the company’s issued share capital (excluding treasury shares) prior to the transaction, were retained as treasury stock. Consequently, the number of issued shares (excluding treasury shares) declined to 248.42 million, while treasury shares increased to 3.17 million. Total issued shares remained unchanged at 251.59 million.

The transaction forms part of the general mandate approved on 26 June 2026, which authorises the company to repurchase up to 24.85 million shares. Cumulative buybacks under this mandate now total 95,500 shares, equal to 0.04% of the shares outstanding on the mandate date, leaving over 99% of the authorised limit available.

In accordance with Hong Kong Stock Exchange regulations, BeautyFarm Med is subject to a moratorium on issuing new shares or disposing of treasury shares until 29 July 2026.